CN102911177A - 7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and synthetic method thereof - Google Patents
7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and synthetic method thereof Download PDFInfo
- Publication number
- CN102911177A CN102911177A CN2012104387279A CN201210438727A CN102911177A CN 102911177 A CN102911177 A CN 102911177A CN 2012104387279 A CN2012104387279 A CN 2012104387279A CN 201210438727 A CN201210438727 A CN 201210438727A CN 102911177 A CN102911177 A CN 102911177A
- Authority
- CN
- China
- Prior art keywords
- quinazoline
- benzo
- dihydro
- diketone
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides 7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and a synthetic method thereof. The method comprises the following steps of: uniformly mixing 3-amino-1,2,4-triazole, p-chlorobenzaldehyde, 2-hydroxyl-1,4-naphthaquinone and p-methylbenzene sulfonic acid with a usage amount of catalyst, heating and stirring, controlling the temperature at 110-125 DEG C and reacting for 2.5-3 hours. The 7-(4-chlorphenyl)5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone prepared according to the invention introduces chlorine atoms, thus having stronger activity and being more beneficial to absorption. The method provided by the invention is green and environment-friendly, and has the characteristics that the raw materials are available, the operation is simple and the yield is high.
Description
Technical field
The present invention relates to a kind ofly 1, the 2-naphthoquinone derivatives specifically, relates to a kind of 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5, the 6-diketone.
Background technology
Cancer is a class disease of serious threat human health, and seeking effective cancer therapy drug is the important research topic of present world medical circle, and according to the literature, 1,2-naphthoquinone derivatives has antitumor, anti-inflammatory, the multiple biological activity such as antibiotic.In recent years 1, the anti-tumor activity of 2-naphthoquinone derivatives gets more and more people's extensive concerning day by day, and some are natural 1, the 2-naphthoquinone compound as:
β1 of-lapachol, Rhinacanthone, Biflorin, mansonone E and synthetic, the 2-naphthoquinone compound all demonstrates unique antitumor action such as: Squamocin A.Compare with the 1,4-naphthoquinone compounds, the antitumor action of 1,2-naphthoquinone compound has following three advantages; 1) antitumour activity is strong, and the 1,4-naphthoquinone of similar and 1,2-naphthoquinone compound, the latter's antitumour activity are than the former large 2-5 doubly; 2) selectivity is good, 1,2-naphthoquinone compound to Normocellular killing action a little less than, have stronger selectivity; 3) topoisomerase is had stronger restraining effect, topoisomerase enzyme inhibitor has indicated a direction for we develop optionally.
Nitrogen heterocyclic is a kind of important intermediate in the Synthetic Organic Chemistry, has a wide range of applications in fine chemistry industry, agricultural chemicals and other relevant industries, and nitrogen heterocyclic also is the key structure segment of some biologically active substance and medicine simultaneously.With nitrogen heterocyclic and the amalgamation of 1,2-naphthoquinones, can obviously increase the activity of compound.
Chlorine-containing organic compounds is owing to its unique physics, and chemical property and biological activity have all adopted chloride compound in many medicines, such as microbiotic paraxin, and antipsychotic drug Torazina, anti-inflammation and analgesic drugs diclofenac etc.
Innovation of the present invention has been to synthesize a kind of nitrogen heterocyclic and 1 that chlorine replaces that contains, and 2-naphthoquinone compound, this compound not yet have report at present.Through preliminary determination of pharmacological activity, this compound has stronger antitumour activity.
Summary of the invention
The purpose of this invention is to provide a kind of new compound 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5, the 6-diketone.
Another object of the present invention provides the synthetic method of this compound.
In order to realize the object of the invention, 7-of the present invention (4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5, the 6-diketone, it is the compound with structure shown in the formula I:
Specifically, of the present invention 1, the 2-naphthoquinone compound is 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5,6-diketone, molecular formula: C
19H
9ClN
4O
2, molecular weight: 360.04, outward appearance: yellow solid, fusing point: 245-246 ℃.
7-of the present invention (4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5, the synthetic method of 6-diketone adopts first with 3-amino-1, the tosic acid of 2,4-triazole, 4-chlorobenzaldehyde, 2 hydroxy 1,4 naphthoquinone (lawsone) and catalyst levels mixes, heated and stirred, temperature are controlled at 110-125 ℃, react 2.5-3 hour.
Wherein, described 3-amino-1,2, the mol ratio of 4-triazole, 4-chlorobenzaldehyde, 2 hydroxy 1,4 naphthoquinone (lawsone) is 1:1 ~ 1.1:1.After the reaction, reaction mixture dissolves with methylene dichloride, water washing twice, and steaming desolventizes, and uses 95% ethyl alcohol recrystallization, obtains 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5, the 6-diketone.
Its reaction formula is:
Embodiment
Following examples are used for explanation the present invention, but are not used for limiting the scope of the invention.
With 0.84g 3-amino-1,2, the 4-triazole, 1.40g 4-chlorobenzaldehyde, 1.74g 2 hydroxy 1,4 naphthoquinone (lawsone) and 0.2g tosic acid place 50 milliliters of reaction flasks to mix together, and heated and stirred, temperature are controlled at 110 ℃, react after 2.5 hours.Reaction mixture dissolves with 20 milliliters of methylene dichloride, 20 ml water washed twice, and anhydrous sodium sulfate drying, steaming desolventizes, and uses 95% ethyl alcohol recrystallization, gets yellow corresponding product 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5,6-diketone 3.17g, productive rate are 88 %.
After testing, molecular formula: C
19H
9ClN
4O
2, molecular weight: 360.04, outward appearance: yellow solid, fusing point: 245-246 ℃;
IR (KBr)
ν: 3074, 2923, 1684, 1598, 1586, 1512, 1501, 1478, 1449, 1296, 1281, 1273, 1228, 1093, 766 cm
-1;
1H NMR (CDCl
3, 400 MHz)
δ: 8.99 (d,
J = 7.6 Hz, 1H, ArH), 8.59 (s, 1H, CH), 8.26 (d,
J = 7.6 Hz, 1H, ArH), 7.97-7.50 (m, 6H, ArH);
13C NMR (CDCl
3, 100 MHz)
δ: 178.6, 178.2, 159.3, 157.3, 155.6, 152.9, 138.2, 136.7, 135.5, 134.9, 133.5, 132.1, 130.4, 130.1, 129.6, 129.3, 128.1, 126.4, 113.9;
C
19H
9ClN
4O
2Constituent content: C 63.26%, H 2.51%, and N 15.53%; Determine: C 63.32%, and H 2.42%, and N 15.60%.
With 8.4g 3-amino-1,2, the 4-triazole, 14.7g 4-chlorobenzaldehyde, 17.4g 2 hydroxy 1,4 naphthoquinone (lawsone) and 2g tosic acid place 250 milliliters of reaction flasks to mix together, and heated and stirred, temperature are controlled at 120 ℃, react after 3 hours.Reaction mixture dissolves with 200 milliliters of methylene dichloride, 200 ml water washed twice, and anhydrous sodium sulfate drying, steaming desolventizes, and uses 95% ethyl alcohol recrystallization, gets yellow corresponding product 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5,6-diketone 31.0g, productive rate are 85 %.
With 42g 3-amino-1,2, the 4-triazole, 77.6g 4-chlorobenzaldehyde, 87g 2 hydroxy 1,4 naphthoquinone (lawsone) and 10g tosic acid place 1000 milliliters of reaction flasks to mix together, and heated and stirred, temperature are controlled at 125 ℃, react after 2.5 hours.Reaction mixture dissolves with 1000 milliliters of methylene dichloride, 1000 ml water washed twice, and anhydrous sodium sulfate drying, steaming desolventizes, and uses 95% ethyl alcohol recrystallization, gets yellow corresponding product 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5,6-diketone 162g, productive rate are 90 %.
Adopt the anti-tumor activity of mtt assay test target compound.Take breast cancer cell MCF-7 as the test cell strain, select the adherent tumour cell of logarithmic phase, after trysinization, be made into the cell suspension of 5000/mL with the RPMI l640 substratum that contains 10% calf serum, be seeded in 96 well culture plates, 200 μ L are inoculated in every hole, 37 ℃, 5%CO
2Cultivate 24 h.Set up negative control group, positive controls and administration group.The substratum that contains the different concns sample that experimental group renews, control group then changes the substratum that contains the equal-volume solvent, and positive controls gives the positive control drug Zorubicin, and (being diluted to concentration with perfect medium is 10 μ molL
-1), establish 3~5 parallel holes for every group, 37 ℃, 5%CO
2Cultivate 4~5d.Abandoning supernatant, every hole add the serum free medium of the freshly prepared 0.2mg/mL of the containing MTT of 200 μ L.37 ℃ are continued to cultivate 4h.Carefully abandon supernatant, and add 200 μ LDMSO, behind miniature ultrasonic vibrator mixing, take tested wavelength as 570nm, reference wavelength is that 450nm measures optical density value on microplate reader.Be calculated as follows medicine to the inhibiting rate of growth of tumour cell: growth of tumour cell inhibiting rate %=(1-OD experiment/OD contrast) * 100%.With 7-(4-chloro-phenyl-)-5,6-dihydro-7a
H-benzo [
h] [1,2,4]-triazole [3,4-also
b] quinazoline-5, mapping can obtain dose response curve to the different concns of 6-diketone to the growth of tumour cell inhibiting rate, therefrom obtains the half casualty-producing concentrations IC of sample
50Its IC
50Value is 5.84 μ g/mL.
Although above the present invention is described in detail with a general description of the specific embodiments, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (4)
- (1.7-4-chloro-phenyl-)-5,6-dihydro-7a H-benzo [ h] 1,2, the 4-triazole is [3,4-also b] quinazoline-5, the 6-diketone, its structural formula is as follows:。
- 2. prepare 7-claimed in claim 1 (4-chloro-phenyl-)-5,6-dihydro-7a H-benzo [ h] 1,2, the 4-triazole is [3,4-also b] quinazoline-5, the synthetic method of 6-diketone is characterized in that, it adopts first with 3-amino-1, the tosic acid of 2,4-triazole, 4-chlorobenzaldehyde, 2 hydroxy 1,4 naphthoquinone (lawsone) and catalyst levels mixes, heated and stirred under 110-125 ℃, was reacted 2.5-3 hour.
- 3. method according to claim 2 is characterized in that, 3-amino-1,2, and the mol ratio of 4-triazole, 4-chlorobenzaldehyde, 2 hydroxy 1,4 naphthoquinone (lawsone) is 1:1 ~ 1.1:1.
- 4. according to claim 2 or 3 described methods, it is characterized in that after the reaction, reaction mixture dissolves with methylene dichloride, water washing twice, steaming desolventizes, and uses 95% ethyl alcohol recrystallization, obtains 7-(4-chloro-phenyl-)-5,6-dihydro-7a H-benzo [ h] 1,2, the 4-triazole is [3,4-also b] quinazoline-5, the 6-diketone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210438727.9A CN102911177B (en) | 2012-11-07 | 2012-11-07 | 7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and synthetic method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210438727.9A CN102911177B (en) | 2012-11-07 | 2012-11-07 | 7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and synthetic method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102911177A true CN102911177A (en) | 2013-02-06 |
CN102911177B CN102911177B (en) | 2014-07-09 |
Family
ID=47609779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210438727.9A Expired - Fee Related CN102911177B (en) | 2012-11-07 | 2012-11-07 | 7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and synthetic method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102911177B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530056A (en) * | 2015-01-07 | 2015-04-22 | 新乡医学院 | Heterozygote of adjacent naphthoquinone and tetrazol-pyrimidine and synthetic method thereof |
CN105461641A (en) * | 2015-12-18 | 2016-04-06 | 新乡医学院 | Beta-lapachol-monastrol heterozygote and preparation method and medical application thereof |
CN105541872A (en) * | 2015-12-18 | 2016-05-04 | 新乡医学院 | Ortho-naphthaquinone derivative, and preparation method and medicinal application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57159786A (en) * | 1981-03-27 | 1982-10-01 | Kazuhiro Maruyama | Quinone derivative having nitrogen-containing hetero- ring, and its preparation |
CN1094402A (en) * | 1992-11-09 | 1994-11-02 | 生化制药有限公司 | Antineoplastic heteronaphthoquinones |
US5476933A (en) * | 1994-11-16 | 1995-12-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Azepine synthesis via a diels-alder reaction |
JP2006206506A (en) * | 2005-01-28 | 2006-08-10 | Dainippon Ink & Chem Inc | Benzimidazolone compound and method for producing the same |
CN101955480A (en) * | 2010-01-28 | 2011-01-26 | 新乡医学院 | Pyrazolo [3,4-b] quinoline compound and preparation method thereof |
-
2012
- 2012-11-07 CN CN201210438727.9A patent/CN102911177B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57159786A (en) * | 1981-03-27 | 1982-10-01 | Kazuhiro Maruyama | Quinone derivative having nitrogen-containing hetero- ring, and its preparation |
CN1094402A (en) * | 1992-11-09 | 1994-11-02 | 生化制药有限公司 | Antineoplastic heteronaphthoquinones |
US5476933A (en) * | 1994-11-16 | 1995-12-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Azepine synthesis via a diels-alder reaction |
JP2006206506A (en) * | 2005-01-28 | 2006-08-10 | Dainippon Ink & Chem Inc | Benzimidazolone compound and method for producing the same |
CN101955480A (en) * | 2010-01-28 | 2011-01-26 | 新乡医学院 | Pyrazolo [3,4-b] quinoline compound and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
崔铁兵等: "萘催化氧化制备1,4-萘醌催化剂活性组分研究", 《郑州大学学报(工学版)》 * |
陈群: "2-氨基-3-氯-1,4-萘醌的合成研究", 《精细石油化工进展》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530056A (en) * | 2015-01-07 | 2015-04-22 | 新乡医学院 | Heterozygote of adjacent naphthoquinone and tetrazol-pyrimidine and synthetic method thereof |
CN105461641A (en) * | 2015-12-18 | 2016-04-06 | 新乡医学院 | Beta-lapachol-monastrol heterozygote and preparation method and medical application thereof |
CN105541872A (en) * | 2015-12-18 | 2016-05-04 | 新乡医学院 | Ortho-naphthaquinone derivative, and preparation method and medicinal application thereof |
CN105461641B (en) * | 2015-12-18 | 2017-11-21 | 新乡医学院 | A kind of β lapachols list star element heterozygote and preparation method thereof and medical usage |
Also Published As
Publication number | Publication date |
---|---|
CN102911177B (en) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101879158B (en) | New application of artemisinin derivant | |
CN106749317B (en) | A kind of azepine penthienate [2,3-d] pyrimidone benzsulfamide analog derivative and purposes | |
CN108117507A (en) | A kind of preparation method and use of azaspiro cyclohexadienone | |
CN102911177B (en) | 7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and synthetic method thereof | |
CN102127024A (en) | Method for synthesizing 4-aryl-1H-1,2,3-triazole by using 1,1-dibromo-1-olefin | |
CN101792438A (en) | Method for synthesizing 1-substituted-1,2,3-tolyltriazole | |
CN104530056B (en) | The heterozygote of a kind of adjacent naphthoquinones and tetrazolo pyrimidine and synthetic method thereof | |
CN112341402B (en) | Preparation method and application of pyrimidine compound capable of inhibiting bacteria in medical care process | |
CN103070868A (en) | IDO inhibitor containing NH-1,2,3-triazole and preparation method thereof | |
CN101274921B (en) | Synthetic method for taurolidine and pharmaceutical preparations | |
CN106748942B (en) | Doxercalciferol analog WXFQ-65 and its synthetic method | |
CN103435560B (en) | Synthesis and application of aceanthrylene [1,2-b] quinoxaline derivative with flexible side chain | |
CN105693738A (en) | 3'-phenyl spirono[indoline-3, 2'-pyrrolidine]-2-ketone derivative and preparation method and application thereof | |
CN109232703A (en) | Containing 16- (1 '-aromatic radical -1 ', 2 ', 3 '-triazoles) methylene-androstane -17- ketone derivatives | |
CN105693609B (en) | Polysubstituted phenyl alkylamino acridone -4- amides compound and its preparation method and application | |
CN104610271B (en) | 12-(2-fluorophenyl)-benzo [h] [1,3] methylene-dioxy [4,5-b] acridine-10,11-diketone and synthetic method thereof | |
CN108079294B (en) | Ferrocene-lanthanide metal compound and preparation method and application thereof | |
CN102584670B (en) | Indole-3-formaldehyde shrinkage phenylenediamine bis-schiff base and preparation method thereof | |
CN106588920A (en) | 1,3-diazabicyclo [1,2-a] quinoline compound as well as preparation method and antitumor application thereof | |
CN107353287B (en) | A kind of quinoxaline and heterocyclic fourth ketone compounds and its application in antitumor | |
CN106946974B (en) | Ursolic amide derivative containing pyrazole heterocycle and synthesis and application thereof | |
CN102382120B (en) | 11-(2, 4-dichlorophenyl) 12H-benzo[f]-furan [3, 4-b] chromene-10(11H)-ketone and synthetic method thereof | |
CN102050795A (en) | Method for synthesizing 1-substituted-1, 2, 3-triazole from sodium acetylide | |
CN104211733B (en) | Benzene ethylene diazene six molybdic acid TBuA and the preparation method of derivative thereof and application | |
CN102942570A (en) | 1-trifluoromethyl-2,8-diazospiro[4.5]decane derivative and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140709 Termination date: 20141107 |
|
EXPY | Termination of patent right or utility model |